Sun Pharma Global recalls osteoporosis drug in US

Published: 15-Mar-2016
Regulatory

After an 'unknown purity' was discovered in cartons of alendronate sodium tablets


Around 380,000 cartons of an osteoporosis drug manufactured by Sun Pharmaceutical Industries are being recalled in the US due to the presence of an 'unknown impurity'.

Sun Pharma Global Fze, an arm of the Indian pharma major, has decided to recall 381,120 cartons of alendronate sodium tablets, which are indicated for the treatment and prevention of osteoporosis in post menopausal women, and to increase bone mass in men with osteoporosis.

The drug is also used in the treatment of glucocorticoid induced osteoporosis, and Paget’s disease of the bone in men and women.

  • Companies:
  • Sun Pharmaceutical Industries
See more

You may also like

Regulatory

Several large Indian pharma companies under US FDA scrutiny

Read more
Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Several large Indian pharma companies under US FDA scrutiny

Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Regulatory

US FDA says Ranbaxy has to forfeit exclusivity for capsules to treat stomach and aesophagus problems

US regulator revokes tentative approvals for two Ranbaxy generics
Regulatory

US FDA to continue to target non-compliant Indian companies

All available enforcement tools to be utilised to bring facilities to compliance to ensure the protection of public health
Media

Bureaucracy is impeding India\'s growth in pharma, says report

Strong commercial opportunities suffering because of government policy, according to latest Business Monitor report
Manufacturing

FDA prohibits manufacture of FDA-regulated drugs from Ranbaxy plant in Mohali

Agency issues import alert and adds this facility to existing consent decree until such time as company complies with cGMP
Regulatory

Indian manufacturers challenge Drug Price Control Order

Move could delay the introduction of low priced medicines in the market
Regulatory

Intellectual property battles rage on

Spate of cases filed recently shows that patent battles are heating up
Subscribe now